Rainbow W.H. Lau

Dr. Rainbow W.H. Lau

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
SCShuk-Ling Chau
Shuk-Ling Chau
JTJoanna Tong
Joanna Tong
CCChit Chow
Chit Chow
JKJohnny Kwan
Johnny Kwan
RLRaymond Lung
Raymond Lung
Ka Fai ToKa Fai To
Ka Fai To
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a subtype of non-small cell lung cancer (NSCLC) characterized by marked lymphocytic infiltration and association with Epstein–Barr virus (EBV). The molecular basis underlying the disease remains unclear. We sought to study the molecular landscape by multiple approaches including whole genomic sequencing, capture-based targeted sequencing, fluorescent in situ hybridization and immunohistochemistry. Tumor cells from 57 EBV-positive pulmonary LELCs were isolated by careful microdissection prior to genomic sequencing. Integrated analysis revealed a distinct genomic landscape of low TP53 mutation rate (11%), low incidence of known drivers in the RTK/RAS/RAF (11%) and PI3K/AKT/mTOR pathways (7%), but enriched for loss-of-function mutations in multiple negative regulators of the NF-κB pathway. High level programmed cell death ligand-1 (PD-L1) expression was shown with 47% and 79% of the cases showing positive PD-L1 immunoreactivity at ≥50% and ≥1% tumor proportion score, respectively. Subsets of the patients with actionable fibroblast growth factor receptor 3 (FGFR3) aberrations (4%) and mismatch repair deficiency (4%) were potentially eligible for precision medicine. Pulmonary LELC showed a distinct genomic landscape, different from major NSCLC subtypes but resembled that of EBV-associated nasopharyngeal carcinoma. Our work facilitated the understanding of molecular basis underlying pulmonary LELC to explore potential therapeutic options.

1 March 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
Calvin NgCalvin Ng
Calvin Ng
RWRandolph H.L. Wong
Randolph H.L. Wong
RLRainbow W.H. Lau
Rainbow W.H. Lau
AYAnthony P.C. Yim
Anthony P.C. Yim

25 September 2023 in Journal of Bronchology & Interventional Pulmonology
Verified
Journal Article
Open access
KLKelvin K.W. Ba Lau
Kelvin K.W. Ba Lau
RLRainbow W.H. Lau
Rainbow W.H. Lau
RBRalitsa Baranowski
Ralitsa Baranowski
JKJulie Bs Krzykowski
Julie Bs Krzykowski
Calvin NgCalvin Ng
Calvin Ng
Background: Image-guided thermal ablation is a minimally invasive local therapy for lung malignancies. NAVABLATE characterized the safety and performance of transbronchial microwave ablation (MWA) in the lung. Methods: The prospective, single-arm, 2-center NAVABLATE study (NCT03569111) evaluated transbronchial MWA in patients with histologically confirmed lung malignancies ≤30 mm in maximum diameter who were not candidates for, or who declined, both surgery and stereotactic body radiation therapy. Ablation of 1 nodule was allowed per subject. The nodule was reached with electromagnetic navigation bronchoscopy. Cone-beam computed tomography was used to verify the ablation catheter position and to evaluate the ablation zone postprocedure. The primary end point was composite adverse events related to the transbronchial MWA device through 1-month follow-up. Secondary end points included technical success (nodule reached and ablated according to the study protocol) and technique efficacy (satisfactory ablation based on 1-month follow-up imaging). Results: Thirty subjects (30 nodules; 66.7% primary lung, 33.3% oligometastatic) were enrolled from February 2019 to September 2020. The pre-procedure median nodule size was 12.5 mm (range 5 to 27 mm). Procedure-day technical success was 100% (30/30), with a mean ablative margin of 9.9±2.7 mm. One-month imaging showed 100% (30/30) technique efficacy. The composite adverse event rate related to the transbronchial MWA device through 1-month follow-up was 3.3% (1 subject, mild hemoptysis). No deaths or pneumothoraces occurred. Four subjects (13.3%) experienced grade 3 complications; none had grade 4 or 5. Conclusion: Transbronchial microwave ablation is an alternative treatment modality for malignant lung nodules ≤30 mm. There were no deaths or pneumothorax. In all, 13.3% of patients developed grade 3 or above complications.

1 November 2017 in Thoracic Surgery Clinics
Verified
Journal Article
Closed access
ZZZe-Rui Zhao
Ze-Rui Zhao
RLRainbow W.H. Lau
Rainbow W.H. Lau
Calvin NgCalvin Ng
Calvin Ng

8 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JCJoyce W.H. Chan
Joyce W.H. Chan
ISIvan C. H. Siu
Ivan C. H. Siu
ACAliss Tsz Ching Chang
Aliss Tsz Ching Chang
MLMolly S. C. Li
Molly S. C. Li
RLRainbow W.H. Lau
Rainbow W.H. Lau
Calvin NgCalvin Ng
Calvin Ng
The demand for parenchyma-sparing local therapies for lung cancer is rising owing to an increasing incidence of multifocal lung cancers and patients who are unfit for surgery. With the latest evidence of the efficacy of lung cancer screening, more premalignant or early-stage lung cancers are being discovered and the paradigm has shifted from treatment to prevention. Transbronchial therapy is an important armamentarium in the local treatment of lung cancers, with microwave ablation being the most promising based on early to midterm results. Adjuncts to improve transbronchial ablation efficiency and accuracy include mobile C-arm platforms, software to correct for the CT-to-body divergence, metal-containing nanoparticles, and robotic bronchoscopy. Other forms of energy including steam vapor therapy and pulse electric field are under intensive investigation.

15 February 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
JCJoyce W Y Chan
Joyce W Y Chan
PYPeter S Y Yu
Peter S Y Yu
JYJack Hong Yang
Jack Hong Yang
EYEvan Qize Yuan
Evan Qize Yuan
HJHao Jia
Hao Jia
Calvin NgCalvin Ng
Calvin Ng
Summary: Surgical access trauma has important detrimental implications for immunological status, organ function and clinical recovery. Thoracic surgery has rapidly evolved through the decades, with the advantages of minimally invasive surgery becoming more and more apparent. The clinical benefits of enhanced recovery after video-assisted thoracoscopic surgery (VATS) may be, at least in part, the result of better-preserved cellular immunity and cytokine profile, attenuated stress hormone release and improved preservation of pulmonary and shoulder function. Parameters of postoperative pain, chest drain duration, hospital stay and even long-term survival are also indirect reflections of the advantages of reduced access trauma. With innovations of surgical instruments, optical devices and operative platform, uniportal VATS, robotic thoracic surgery and non-intubated anaesthesia represent the latest frontiers in minimizing trauma from surgical access.